I am an expert in tumor-infiltrating lymphocyte (TIL) therapy, a form of immunotherapy that uses your own immune cells to attack your tumor. I currently lead Fred Hutch’s TIL program, one of only four in the U.S. that offers clinical trials to patients. TILs are a type of T cell that attacks cancer, but tumors can turn off this immune response. We can extract the dormant cells from a piece of tumor, reactivate them in the lab, multiply the cells to the billions in the laboratory and reinfuse them into patients to fight cancer.

I believe that enhancing your own immune system’s natural ability to recognize and attack cancer cells is perhaps the most promising new form of treatment, and many clinical trials are available for you to explore.

We plan to expand T-cell therapy to head and neck cancer, allowing your immune system to recognize and attack cancer cells in your body. I am committed to extending the benefits of this new immunotherapy to as many patients as possible.